LA JOLLA, Calif.--Genomics company Sequana Therapeutics here has earned a milestone payment from Glaxo Wellcome in recognition of its success in identifying certain regions of DNA that contain genes associated with noninsulin-dependent diabetes. "This is an important step toward finding the genes responsible for diabetes," commented Callum Bell, Sequana's project leader for diabetes research. "Combining Sequana's high-technology gene discovery platform with Glaxo Wellcome's expertise in the field of diabetes has permitted very rapid progress," he added.